Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Doxercalciferol (TSA 840) is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 8,500 | |||
2 mg | 在庫あり | ¥ 12,000 | |||
5 mg | 在庫あり | ¥ 18,500 | |||
10 mg | 在庫あり | ¥ 29,000 | |||
25 mg | 在庫あり | ¥ 66,000 | |||
50 mg | 在庫あり | ¥ 124,000 | |||
100 mg | 在庫あり | ¥ 179,000 | |||
500 mg | 在庫あり | ¥ 372,000 |
説明 | Doxercalciferol (TSA 840) is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease. |
In vivo | Doxercalciferol (100 or 300 pg/g b.w.) normalizes serum calcium and parathyroid hormone (PTH) levels in nephrectomy treated mice. Doxercalciferol (300 pg/g b.w.) significantly reduces osteitis fibrosa in nephrectomy treated mice. [1] Doxercalciferol results in significant decrease in cardiac hypertrophy and improves cardiac function in rats fed a high salt (HS) diet. Doxercalciferol treatment leads to a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level in rats fed a high salt (HS) diet. Doxercalciferol also significantly reduces the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency. [2] Doxercalciferol decreases proteinuria, podocyte injury, mesangial expansion, and extracellular matrix protein accumulation in Diet-induced obesity (DIO) mice. Doxercalciferol also decreases macrophage infiltration, oxidative stress, proinflammatory cytokines, and profibrotic growth factors in DIO mice. Doxercalciferol also prevents the activation of the renin-angiotensin-aldosterone system including the angiotensin II type 1 receptor and the mineralocorticoid receptor in DIO mice. [3] Doxercalciferol combined with Losartan most effectively prevents albuminuria, restored glomerular filtration barrier structure, and dramatically reduces glomerulosclerosis in a dose-dependent manner in mice. Doxercalciferol combined with Losartan virtually prevents morphological and molecular changes in diabetic kidneys of mice. [4] |
別名 | TSA 840, Hectorol, 1.alpha.-Hydroxyvitamin D2, 1α-hydroxyvitamin D2 |
分子量 | 412.65 |
分子式 | C28H44O2 |
CAS No. | 54573-75-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20.6 mg/mL (50 mM)
DMSO: 4.1 mg/mL (10 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Doxercalciferol 54573-75-0 Others TSA840 1a-hydroxyvitamin D2 Vitamin D receptor 1alpha-hydroxyvitamin D2 inhibit TSA 840 Inhibitor Hectorol Vitamin D TSA-840 1.alpha.-Hydroxyvitamin D2 VD/VDR 1α-hydroxyvitamin D2 inhibitor